Vermillion launches ASPiRA LABS to address management of gynecologic cancers

April 30, 2014

Vermillion has launched ASPiRA LABS, which will specialize in applying the latest biomarker-based technologies to address critical needs in the management of gynecologic cancers.

“We felt it was important to build our own lab to create a dedicated diagnostic and education resource for this area of critical need,” says James LaFrance, chairman, president, and chief executive officer of Vermillion. “Through ASPiRA LABS, we are focused on shifting healthcare delivery to a model that values the most informed decisions to improve outcomes for women.”

Integral to this effort is ASPiRA’s specialization in OVA1, a highly sensitive, FDA-cleared clinical decision support diagnostic tool used by obstetricians/gynecologists in the management of patients with suspicious adnexal masses prior to first surgery. OVA1 measures the levels of five protein biomarkers found in the blood—B2 Microglobulin; CA 125II; Apoliprotein; Prealbumin; and Transferrin—and then uses proprietary software called OvaCalc to calculate a single risk score for malignancy. Detection of ovarian cancer included epithelial, non-epithelial, and early-stage malignancies. This evidence suggests that OVA1 may promote more sensitive identification of ovarian cancers among women undergoing surgery for an adnexal mass. Once identified, patients are referred or consulted with a gynecologic oncologist, supporting best practices in ovarian cancer care.

In addition to OVA1, which is also available through Quest Diagnostics, ASPiRA LABS will offer physicians longitudinal CA 125II testing. The CA 125II baseline level is obtained from OVA1 testing prior to initial surgery and diagnosis of ovarian cancer. Read more about ASPiRA LABS.

Read more